Interplay between epigenetic mechanisms and transcription factors in atherosclerosis

Atherosclerosis. 2024 Aug:395:117615. doi: 10.1016/j.atherosclerosis.2024.117615. Epub 2024 Jun 6.

Abstract

Cardiovascular diseases (CVD), including coronary heart disease and stroke, comprise the number one cause of mortality worldwide. A major contributor to CVD is atherosclerosis, which is a low-grade inflammatory disease of vasculature that involves a pathological build-up of plaque within the arterial walls. Studies have shown that regulation of gene expression via transcription factors and epigenetic mechanisms play a fundamental role in transcriptomic changes linked to the development of atherosclerosis. Chromatin remodeling is a reversible phenomenon and studies have supported the clinical application of chromatin-modifying agents for the prevention and treatment of CVD. In addition, pre-clinical studies have identified multiple transcription factors as potential therapeutic targets in combating atherosclerotic CVD. Although interaction between transcription factors and epigenetic mechanisms facilitate gene regulation, a limited number of studies appreciate this crosstalk in the context of CVD. Here, we reviewed this gene regulatory mechanism underappreciated in atherosclerosis, which will highlight the mechanisms underlying novel therapeutics targeting epigenetic modifiers and transcription factors in atherosclerosis.

Keywords: Atherosclerosis; Cardiovascular diseases; Chromatin remodeling; Epigenetic modifiers; Epigenetics; Transcription factor.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atherosclerosis* / genetics
  • Atherosclerosis* / metabolism
  • Chromatin Assembly and Disassembly
  • DNA Methylation
  • Epigenesis, Genetic*
  • Gene Expression Regulation
  • Genetic Predisposition to Disease
  • Humans
  • Plaque, Atherosclerotic
  • Transcription Factors* / genetics
  • Transcription Factors* / metabolism

Substances

  • Transcription Factors